Abstract Epstein-Barr virus (EBV), a γ-herpesvirus, is the first identified oncogenic virus,
which establishes permanent infection in humans. EBV causes infectious mononucleosis
and is also tightly linked to many malignant diseases. Various vaccine formulations
underwent testing in different animals or in humans. However, none of them was able to
prevent EBV infection and no vaccine has been approved to date. Current efforts focus on
antigen selection, combination, and design to improve the efficacy of vaccines. EBV …